Extended‐Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real‐World Retrospective Study

作者
Ryo� Saito,Wataru Sasaki,Haruka Watanabe,Momoka Hashimoto,Rina Kamigaki,Kento Nagiri,Akio Tanaka
出处
期刊:Journal of Dermatology [Wiley]
卷期号:53 (8): 1179-1183
标识
DOI:10.1111/1346-8138.70350
摘要

This retrospective study evaluated the clinical courses and treatment patterns of 81 patients with atopic dermatitis (AD) treated with dupilumab at Hiroshima University Hospital. Patients were categorized into six groups based on their clinical outcomes, including those who continued treatment, achieved remission and discontinued, or discontinued due to adverse effects or insufficient efficacy. Of the 81 patients, 38 (47%) continued treatment throughout the study period, and 16 (20%) achieved remission and discontinued treatment without relapse. Analysis of baseline severity using EASI and TARC levels revealed no significant differences between these groups, suggesting that baseline severity does not predict long-term therapeutic outcomes. Regarding concomitant topical therapy, although the potency of topical corticosteroids (TCS) remained unchanged in most patients, the total dosage was significantly reduced by a mean of 71.3%, reflecting a successful transition to proactive therapy or a reduced affected body surface area. Furthermore, this study investigated the feasibility of extending dupilumab dosing intervals. Nearly half of the patients extended their intervals including every 3 weeks (Q3W), Q4W, and up to Q8W by 6 months without exacerbation. By 12 months, 22 of the 40 evaluable patients successfully transitioned to extended intervals up to Q12W. These findings suggest that baseline disease severity does not necessarily predict the long-term clinical course of dupilumab therapy in patients with AD. Although TCS potency is often maintained to ensure stability, the dosage can be drastically reduced. Furthermore, a subset of patients can discontinue or extend the dosing intervals, and the optimal timing for extending intervals is more flexible and can be initiated earlier than currently suggested by previous reports.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
liao完成签到,获得积分10
1秒前
1秒前
1秒前
激情的怜晴完成签到,获得积分10
1秒前
夜子完成签到,获得积分10
2秒前
芝士完成签到 ,获得积分10
2秒前
米露完成签到 ,获得积分10
2秒前
纯情的阁发布了新的文献求助150
2秒前
隐形曼青的应助被孤独的冷安采纳,获得10
2秒前
烟花的应助被陆羽采纳,获得10
3秒前
纯情的阁发布了新的文献求助10
3秒前
纯情的阁发布了新的文献求助10
3秒前
陈陈完成签到 ,获得积分10
3秒前
daidai完成签到 ,获得积分10
3秒前
乐乐的应助被kj采纳,获得10
3秒前
wang完成签到,获得积分10
4秒前
Whywhy完成签到,获得积分10
4秒前
秋彤发布了新的文献求助20
4秒前
阳光的小土豆完成签到,获得积分20
4秒前
4秒前
5秒前
百十余发布了新的文献求助10
5秒前
隔壁老王发布了新的文献求助10
5秒前
早点睡觉完成签到 ,获得积分10
5秒前
Nowaki发布了新的文献求助10
5秒前
6秒前
星辰大海的应助被八木采纳,获得10
6秒前
赵一晨发布了新的文献求助10
6秒前
纯情的阁发布了新的文献求助10
6秒前
可莉完成签到 ,获得积分0
6秒前
6秒前
6秒前
纯情的阁发布了新的文献求助20
6秒前
李健的应助被还单身的香旋采纳,获得10
7秒前
7秒前
7秒前
南天七完成签到 ,获得积分10
8秒前
8秒前
9秒前
纯情的阁发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163922
求助须知:如何正确求助?哪些是违规求助? 9557995
关于积分的说明 21743022
捐赠科研通 7754548
什么是DOI,文献DOI怎么找? 3428401
关于科研通互助平台的介绍 2553053
邀请新用户注册赠送积分活动 2473008